Literature DB >> 25027336

Evaluation of chronic rhinosinusitis management using the SNOT-22 in adult cystic fibrosis patients.

V Savastano1, S Bertin, T Vittori, C Tripodi, G Magliulo.   

Abstract

OBJECTIVES: Sinonasal disease (SND) is a common finding in subjects with Cystic Fibrosis (CF). Even though it does not play a key role in the life expectancy of these patients, it increases the morbidity rate of CF, with deterioration of the quality of life and of general health status. The aim of this study is the evaluation of the impact of sinonasal disease and Extensive Endoscopic Sinus Surgery (eESS) on the quality of life (QOL) of CF patients by means of the 22 item Sino-Nasal Outcome Test (SNOT-22) and define if there is a correlation between SNOT-22 and the Lund-Mackay score. PATIENTS AND METHODS: We performed a prospective study in 33 CF patients with medically refractory SND. The extent of polyposis was graded both endoscopically and on computed tomography images in accordance with the Lund-Mackay score. All patients underwent eESS. The SNOT was administered in order to assess the quality of life related to SND both before surgery and during follow-up at 6 months, 1 year and 2 years postoperatively.
RESULTS: The SNOT-22 and Lund-Mackay score showed a remarkable mean improvement during follow-up. The differences between the initial examination and last score were significant (p < 0.001), but there was no statistic correlation between SNOT-22 and Lund-Mackay.
CONCLUSIONS: More attention should be paid to sinonasal symptoms in CF patients and SNOT-22 is a simple and effective tool for this purpose. This score is also important for indicating the outcome of the eESS procedure. In all patients SNOT showed a significant improvement in QoL.

Entities:  

Mesh:

Year:  2014        PMID: 25027336

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

Review 1.  Sino-Nasal outcome test-22 outcomes after sinus surgery: A systematic review and meta-analysis.

Authors:  Zachary M Soler; Rabun Jones; Phong Le; Luke Rudmik; Jose L Mattos; Shaun A Nguyen; Rodney J Schlosser
Journal:  Laryngoscope       Date:  2017-11-22       Impact factor: 3.325

2.  Sinonasal characteristics and quality of life by SNOT-22 in adult patients with cystic fibrosis.

Authors:  Suzie Hyeona Kang; Camila Degen Meotti; Karine Bombardelli; Otávio Bejzman Piltcher; Paulo de Tarso Roth Dalcin
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-18       Impact factor: 2.503

3.  Longitudinal improvement and stability of the SNOT-22 survey in the evaluation of surgical management for chronic rhinosinusitis.

Authors:  Adam S DeConde; Jess C Mace; Jeremiah A Alt; Luke Rudmik; Zachary M Soler; Timothy L Smith
Journal:  Int Forum Allergy Rhinol       Date:  2014-12-15       Impact factor: 3.858

4.  Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in cystic fibrosis.

Authors:  Amanda L Stapleton; Adam J Kimple; Jennifer L Goralski; S Mehdi Nouraie; Barton F Branstetter; Amber D Shaffer; Joseph M Pilewski; Brent A Senior; Stella E Lee; Anna C Zemke
Journal:  J Cyst Fibros       Date:  2022-03-14       Impact factor: 5.527

5.  Changes of Proteases, Antiproteases, and Pathogens in Cystic Fibrosis Patients' Upper and Lower Airways after IV-Antibiotic Therapy.

Authors:  Ulrike Müller; Julia Hentschel; Wibke K Janhsen; Kerstin Hünniger; Uta-Christina Hipler; Jürgen Sonnemann; Wolfgang Pfister; Klas Böer; Thomas Lehmann; Jochen G Mainz
Journal:  Mediators Inflamm       Date:  2015-06-21       Impact factor: 4.711

Review 6.  Clinical chronic rhinosinusitis outcomes in pediatric patients with cystic fibrosis.

Authors:  Frank W Virgin
Journal:  Laryngoscope Investig Otolaryngol       Date:  2017-05-31

7.  Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations.

Authors:  Adam J Kimple; Brent A Senior; Edward T Naureckas; David A Gudis; Ted Meyer; Sarah E Hempstead; Helaine E Resnick; Dana Albon; Wayne Barfield; Margo McKenna Benoit; Daniel M Beswick; Eliza Callard; Shelagh Cofer; Veronica Downer; E Claire Elson; Angela Garinis; Ashleigh Halderman; Lisa Hamburger; Meagan Helmick; Michael McCown; Cameron J McKinzie; Hanna Phan; Kenneth Rodriguez; Ronald C Rubenstein; Ashley Severin; Gopi Shah; Ambika Shenoy; Brittney Sprouse; Frank Virgin; Bradford A Woodworth; Stella E Lee
Journal:  Int Forum Allergy Rhinol       Date:  2022-02-22       Impact factor: 5.426

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.